Associations between IKZF1 alterations, subtypes and outcomes were also examined in a cohort of children with NCI standard risk (SR) B-ALL or high-risk (HR) B-ALL, with favorable cytogenetic features, from the Molecular Profiling to Predict Responses to Therapy (MP2PRT) study (31) We identified the combination of IKZF1 Δ4–7 and unfavorable genomic subtype and genomics-based definition of IKZF1plus with focal IKZF1 deletions as optimal predictors of relapse in children with B-ALL. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.